Loading organizations...
§ Private Profile · Irvine, CA, USA
JenaValve Technology is a technology company.
JenaValve Technology develops transcatheter heart valve solutions, notably the Trilogy Transcatheter Heart Valve System. This system offers the first FDA-approved, minimally invasive treatment for high-risk patients with severe, symptomatic aortic regurgitation. Its locator technology ensures precise commissural alignment and secure valve attachment to native leaflets, even where calcification is absent.
Co-founded in 2006 by distinguished cardiologist Hans-Reiner Figulla, JenaValve addressed the critical unmet need for a dedicated transcatheter solution for aortic regurgitation. Traditional TAVR devices struggled with secure anchoring in these patients, prompting development of a system engineered to overcome these anatomical challenges.
JenaValve serves cardiologists and cardiac surgeons, providing a less invasive alternative for patients at high risk for open-heart surgery. The company's vision is to advance structural heart disease treatment, delivering innovative transcatheter technologies that address clinical gaps and improve patient outcomes.
JenaValve Technology has raised $348.7M across 8 funding rounds.
JenaValve Technology has raised $348.7M in total across 8 funding rounds.
JenaValve Technology has raised $348.7M in total across 8 funding rounds.
JenaValve Technology's investors include Bain Capital Life Sciences, Andera Partners, Deerfield Management, INKEF Capital, Cormorant Asset Management, Gimv, Innovatus Capital Partners, Peijia Medical, Pictet Alternative Advisors, Qatar Investment Authority, RMM, Valiance.
JenaValve Technology has raised $348.7M across 8 funding rounds. Most recently, it raised $100.0M Series C in August 2022.
JenaValve Technology is a global medical device company specializing in innovative transcatheter heart valve therapies, primarily targeting severe aortic regurgitation (AR) and aortic stenosis (AS). Their flagship product, the JenaValve Trilogy System, is designed to provide a minimally invasive alternative to surgical valve replacement for patients at high or greater risk for surgery. The company serves cardiologists and cardiac surgeons by offering advanced solutions that address unmet clinical needs in structural heart disease, improving patient outcomes and expanding treatment options[1][3].
Founded in 2013 and headquartered in Irvine, California, JenaValve has built momentum through clinical trials and regulatory approvals in the US and Europe. Their technology is notable for its dedicated design to treat AR, a condition traditionally underserved by transcatheter therapies. The company’s growth is driven by ongoing clinical validation, including pivotal trials like ALIGN-AR, and expanding physician adoption[1][2][3].
JenaValve’s origins trace back to pioneering work by Professors Hans Figulla, MD, and Markus Ferrari, MD, at Friedrich Schiller University, who developed the original design concept for a transcatheter aortic valve replacement (TAVR) device addressing both aortic stenosis and regurgitation. The company was officially established in 2013 to develop this innovative valve technology, culminating in patented designs and successful preclinical studies. Over 30 years of development preceded the company’s formal founding, reflecting a long-term commitment to advancing TAVR therapies[1][2].
Key leadership includes executives with decades of experience in medical devices and cardiovascular innovation, such as John (joined 2019) and Jeff, who have led multiple successful startups and strategic transactions in the sector. Their expertise has guided JenaValve through regulatory milestones and market expansion[1].
JenaValve is riding the global trend toward minimally invasive cardiovascular therapies, particularly the expansion of TAVR beyond aortic stenosis to address aortic regurgitation. This timing is critical as the aging population and high surgical risk patients create growing demand for less invasive options. Market forces such as increasing physician expertise in catheter-based interventions and regulatory pathways favoring innovative devices support JenaValve’s growth. By addressing a previously underserved patient segment, JenaValve influences the structural heart disease ecosystem, pushing forward the boundaries of transcatheter valve therapy[1][3].
Looking ahead, JenaValve is poised to expand its clinical footprint and regulatory approvals, particularly in the US market where its Trilogy System remains investigational. Trends shaping its journey include advances in valve design, growing acceptance of TAVR for diverse valve pathologies, and increasing integration of heart teams in patient management. The company’s influence is likely to grow as it continues to demonstrate long-term outcomes and broadens indications, potentially setting new standards in the treatment of aortic regurgitation and stenosis. This aligns with its mission to transform care for severe aortic valve disease, offering hope to patients who previously had limited options[1][3].